Feature | May 16, 2014

Wake Forest Baptist Finds Success With Novel Lung Cancer Treatment

 Lung 3D from CT scan

May 16, 2014 — An old idea of re-treating lung tumors with radiation is new again, especially with the technological advances seen in radiation oncology over the last decade. The Comprehensive Cancer Center of Wake Forest Baptist Medical Center is one of only a handful of cancer centers that is attempting to give lung cancer patients out of treatment options a chance to keep the cancer at bay. For these patients, hope lies in a second course of treatment – repeat radiation. Two complementary papers published back-to-back recently in the journal Radiotherapy and Oncology and the Journal of Thoracic Oncology outline the treatment success at Wake Forest Baptist.

“One of the toughest challenges of lung cancer is what to do for patients when the cancer comes back in an area that’s been treated previously with radiation treatment,” said James J. Urbanic, M.D., lead author of the studies and a radiation oncologist at Wake Forest Baptist. “With some of the technological advances in radiation treatments that have occurred in the last five to 10 years, we’re beginning to re-look at the issue and ask – can we target the radiation precisely enough and with a high enough dose to knock the cancer back?”

Urbanic said the overall findings of the study suggest that there are some patients with recurrent lung cancers who can be treated with another definitive course of radiation therapy and still have a chance at a cure. “At many cancer treatment centers, these patients only get chemotherapy and have no chance at definitive treatment. The goal of treatment is solely to prevent or delay symptoms from developing, and they are seen as incurable,” he said. “But with re-irradiation, our study shows that maybe we can give a curative intent treatment that we couldn’t do in the past. It’s a layer of hope for some patients that they never had before.”

For this study, the researchers looked back at 11 years of clinical data. Eighty-six patients were identified as receiving at least two courses of thoracic radiotherapy. Of that number, 33 were treated with repeat thoracic radiotherapy using stereotactic body radiation therapy (SBRT) or accelerated hypofractionated radiotherapy (AHRT) as a component of their treatment. The median age was 66 and the majority of patients (88 percent) were treated for primary lung cancer. Average tumor size at retreatment was 2.5 cm. Prior lung resections had been completed in 24 percent of patients.

Urbanic said the typical patient is an older man or woman who was treated with either chemotherapy and radiation or radiation alone for a lung cancer that couldn’t be surgically removed. They’ve returned for a checkup and feel well, but a CT (computed tomography) scan shows that the cancer has returned in the area previously treated. If the cancer is just in one spot, the patients get retreated with 10 radiation treatments done with the SBRT technique, which is tightly targeted to just the tumor and minimizes the dose to the surrounding normal tissue.

“Wake Forest Baptist has been developing expertise in doing this,” Urbanic said. “We’re finding that there are patients who are alive years later. We have seen relatively modest toxicity and a good ability to try and control the disease – upwards of 70 percent of the time.”

But there is a higher risk of injury involved when someone is radiated a second time, which is why other cancer treatment center programs might be reluctant to adopt the practice, he said.

“This is a fairly niche effort in lung cancer care, and we’d like to see a national level clinical trial at some point,” he said. “The technology has gotten to the point where I think it’s going to allow radiation oncologists to reassess their ability so that maybe they can take risks they weren’t willing to take before. Eventually, this practice will become more widespread.”

Co-authors include Jeremy M. Kilburn, M.D., Jeffrey G. Kuremsky, M.D., A. William Blackstock, M.D., Michael T. Munley, Ph.D., William T. Kearns, M.S., William H. Hinson, Ph.D., James F. Lovato, M.S., Antonius A. Miller, M.D., and William J. Petty, M.D., all of Wake Forest Baptist.

For more information: www.wakehealth.edu

Related Content

New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
University Medical Center Groningen Performs First Automatic Log-based Proton Therapy Patient QA
News | Proton Therapy | June 14, 2019
IBA announced the physics team of University Medical Center Groningen (UMCG) in the Netherlands has developed and...
ASTRO Applauds New Prior Authorization Legislation
News | Radiation Therapy | June 07, 2019
The American Society for Radiation Oncology (ASTRO) released a statement applauding Congress’s introduction of...
IBA Dosimetry Launches myQA iON
News | Quality Assurance (QA) | June 07, 2019
IBA (Ion Beam Applications S.A.) announced the launch of myQA iON at the 2019 Particle Therapy Co-Operative Group (...
Study Identifies MRI-Guided Radiation Therapy as Growing Market Segment
News | Image Guided Radiation Therapy (IGRT) | June 06, 2019
Revenues from the magnetic resonance imaging (MRI)-guided radiation therapy systems market exceeded $220 million in...
SIIM and ACR Host Machine Learning Challenge for Pneumothorax Detection and Localization
News | Artificial Intelligence | June 03, 2019
The Society for Imaging Informatics in Medicine (SIIM) and the American College of Radiology (ACR) are collaborating...
RefleXion Opens New Manufacturing Facility for Biology-guided Radiotherapy Platform
News | Radiation Therapy | May 31, 2019
RefleXion Medical recently announced the opening of its new manufacturing facility at its headquarters in Hayward,...
AI Biomarker Demonstrates High Predictive Power for Lung Cancer Immunotherapy
News | Artificial Intelligence | May 31, 2019
Lunit announced an abstract presentation of its artificial intelligence (AI) precision medicine research portfolio at...
Vast Majority of Heavy Smokers Not Screened for Lung Cancer
News | Lung Cancer | May 29, 2019
Out of more than 7 million current and former heavy smokers, only 1.9 percent were screened for lung cancer in 2016...